Literature DB >> 1537382

Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.

S I Tamura1, H Asanuma, Y Ito, Y Hirabayashi, Y Suzuki, T Nagamine, C Aizawa, T Kurata, A Oya.   

Abstract

Intranasal (i.n.) vs. subcutaneous (s.c.) administration of influenza hemagglutinin (HA) vaccine was systematically compared in BALB/c mice. Mice were immunized with different vaccines, together with cholera toxin B subunit as an adjuvant, and 4 weeks later were challenged with either a small (2 microliters) or a large (20 microliters) volume of mouse-adapted A/Guizhou-X (H3N2) virus, each of which gave virgin mice either a nasal or a lung predominant infection. Both i.n. and s.c. inoculations of A/Guizhou-X vaccine conferred almost complete protection against both challenges, i.n. inoculation of A/Fukuoka (H3N2) or A/Sichuan (H3N2) vaccine conferred almost complete cross-protection against 2-microliters challenge and a partial cross-protection against 20-microliters challenge, whereas the s.c. inoculation conferred no cross-protection against 2-microliters challenge with a partial cross-protection against 20-microliters challenge. Moreover, i.n. immunization of PR8 (H1N1) vaccine gave a slight cross-protection against 2-microliters challenge, while the s.c. inoculation did not. The degree of protection was easily improved by i.n. inoculation of higher doses of vaccine, but not by the s.c. inoculation. In parallel with the protection, the i.n. vaccination produced a high level of cross-reacting IgA and IgG antibody to A/Guizhou-X HA in nasal and broncho-alveolar washes, while the s.c. vaccination produced the cross-reacting IgG antibody alone. Thus, i.n. inoculation with inactivated vaccines, which induces cross-reacting anti-HA IgA antibody as well as IgG antibody, is more effective than s.c. vaccination for providing cross-protection against drift viruses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537382     DOI: 10.1002/eji.1830220228

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

1.  Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract.

Authors:  J W Simecka; R J Jackson; H Kiyono; J R McGhee
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins.

Authors:  P J Giannasca; J A Boden; T P Monath
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Authors:  Yoshihiko Terauchi; Kaori Sano; Akira Ainai; Shinji Saito; Yuki Taga; Kiyoko Ogawa-Goto; Shin-Ichi Tamura; Takato Odagiri; Masato Tashiro; Mikiya Fujieda; Tadaki Suzuki; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

4.  Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.

Authors:  Dirk Kuck; Tobias Lau; Barbara Leuchs; Andrea Kern; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota.

Authors:  Hisako Yasui; Junko Kiyoshima; Tetsuji Hori
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 7.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

8.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

9.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

10.  Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Authors:  Hideki Hasegawa; Takeshi Ichinohe; Akira Ainai; Shin-Ichi Tamura; Takeshi Kurata
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.